On September 26, 2022 Cerus Corporation (Nasdaq:CERS) reported a selection of abstracts and an industry workshop at the 2022 AABB Annual Meeting, taking place in Orlando, FL from October 1 through October 4 (Press release, Cerus, SEP 26, 2022, View Source [SID1234621410]). This year’s AABB Annual Meeting attracts individuals and institutions from around the globe involved in the fields of transfusion medicine and biotherapies. This year marks the first time the conference has taken place in person since 2019, as well as its 75th anniversary.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The following is a select list of presentations and abstracts of interest for Cerus. All presentation times are listed in Eastern Daylight Time (EDT).

Oral Presentations

Sunday, October 2, 2022 – 4:30 p.m.– Impact of 100% Pathogen Reduction and 7-Day Storage on Platelet Safety and Availability in France – Plenary Abstract Session
Monday, October 3, 2022 – 7:00 a.m. – Cerus Industry Workshop
Poster Presentations

Held between Sunday, October 2 and Monday, October 3, 2022

Impact of Pathogen Reduction (PR) vs. LVDS Testing on Platelet Availability: A Study Based on Real-Life Experience
Comparing Usable Shelf-Life of Pathogen Reduced Platelets vs LVDS Screened Platelets
Pathogen Reduced Cryoprecipitated Fibrinogen Complex Restores Fibrinogen Levels, Clot Firmness and Thrombin Generation in a Hemodilution Model
Survival and Growth of Bacteria during Manufacturing and Storage of Cryo-AHF Compared to Pathogen Reduced Cryoprecipitated Fibrinogen Complex
The full program of Cerus-related abstracts can be found at the following link: View Source

Cerus representatives will be in the exhibition area at booth #1108.

On September 26, 2022 Novo Nordisk reported that initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules") (Filing, 6-K, Novo Nordisk, SEP 26, 2022, View Source [SID1234621409]). This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during a 12-month period beginning 2 February 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the programme initiated 3 August 2022, Novo Nordisk will repurchase B shares for an amount up to DKK 4.4 billion in the period from 4 August 2022 to 31 October 2022.

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

With the transactions stated above, Novo Nordisk owns a total of 20,912,478 B shares of DKK 0.20 as treasury shares, corresponding to 0.9% of the share capital. The total amount of A and B shares in the company is 2,280,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 24 billion during a 12-month period beginning 2 February 2022. As of 23 September 2022, Novo Nordisk has since 2 February 2022 repurchased a total of 19,201,699 B shares at an average share price of DKK 768.92 per B share equal to a transaction value of DKK 14,764,625,404.

On September 26, 2022 Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, reported that it will report financial results for its third quarter of fiscal 2022 ended August 31, on Thursday, October 13, 2022 (Press release, Theratechnologies, SEP 26, 2022, View Source [SID1234621408]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The conference call will be held at 8:30 a.m. (ET) on October 13, 2022 to discuss the results and recent business updates. The call will be hosted by Paul Lévesque, President and Chief Executive Officer. Joining Mr. Lévesque on the call will be other members of the management team, including Chief Financial Officer Philippe Dubuc and Chief Medical Officer Christian Marsolais, who will be available to answer questions from participants following prepared remarks.

On September 26, 2022 Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company) a leader in the development of targeted radiotherapies, reported that it will present at the Cantor Fitzgerald Oncology, Hematology & HemOnc Conference, which is being held on September 28th at the Lotte New York Palace Hotel. Actinium’s Chief Medical Officer, Dr. Avinash Desai, will be participating in a panel titled, "Addressing Challenges in Cell Therapy and Transplant" (Press release, Actinium Pharmaceuticals, SEP 26, 2022, View Source [SID1234621407]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In addition, members of the executive team will be available for one-on-one meetings with conference attendees. Those interested in scheduling a meeting may do so by contacting their Cantor Fitzgerald representative.

On September 26, 2022 Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, reported that management will participate in a fireside chat at the Bank of America Securities Precision Oncology Conference taking place virtually on Monday, October 3 at 10:40 a.m. ET (Press release, Arvinas, SEP 26, 2022, View Source [SID1234621406]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the presentation will be available here and on the Events + Presentations section of the Company’s website.